Download programme pdf document
The organisation keeps the right to make changes to the programme at any time.
-
08:00
CxO breakfast meeting: for CEOs, CFOs, COOs and CBOs active in the life sciences sector
Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.
-
08:00
Investors forum part 1 - breakfast session -
The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, med tech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.
-
08:45
Exhibition and Innovation square
Present your company, products, technology or service. Open from 08:45 till 19:30 hours.
The Innovation square is hosted by V.O.Patents & Trademarks -
09:30
-
Our chair, Ida Haisma, Director Leiden Bio Science Park will guide us through the plenary programme.
-
Hosted by Leiden Bio Science Park
Opening by Carmen van Vilsteren, Chair Top Sector Life Science & Health
-
by Dr. Menzo Havenga, President & CEO Batavia Biosciences
There is a constant demand for more affordable vaccines for global health (polio, measles, rubella), as well as new vaccines to protect against emerging virus outbreaks, such as Ebola, Lassa, Marburg, and coronavirus. To keep up with such demand, breakthrough technologies and global collaborations are required that allow flexible, cost-effective and rapid vaccine development. In this presentation, promising novel technologies, flexible manufacturing solutions and views on collaborations within the industry will be presented. These innovations have demonstrated to substantially lower the cost of goods and increase speed of manufacturing. Such innovations are deemed critical to stay ahead of the game and keep millions of people from dying from vaccine preventable diseases.
-
by Arjen Schippers, Senior Director and Program Head at Europe Cell Therapy Facility, Bristol Myers Squibb Leiden
-
Hosted by Health~Holland, Dr. ir. C.G.P. (Chrétien) Herben, Manager Valorisation
-
-
10:55
Time for networking and to visit the exhibition and innovation square.
-
11:30
Parallel morning sessions
The Nagoya protocol: its impact on research and development in life sciences
Hosted by V.O.Patents & Trademarks
Presentations by:
▪ Martin Brink, Policy Advisor at Centre for Genetic Resources, WUR
▪ Erik de Vroom, Senior Patent Attorney at DSM Intellectual Property
▪ Carolina dos Santos Ribeiro, Senior Policy Advisor at RIVM - Center for Infectious Desease Control (CIB)Advanced biopharmaceutical manufacturing
Hosted by Pivot Park
Presentations by:
▪ Mireille Sanders, Chief Operations Officer at Pharming Group N.V.
▪ Ardena, speaker t.b.a.
▪ Nettie Buitelaar, Business Development at BiosanaPharmaMedical devices to respond to urgent needs
Hosted by Quality by Design
Presentations by
▪ Steven Vinkx, QA & Regulatory Project Engineer at Quality by Design
▪ Koen Beyers, Founder & Board Member at Voxdale
▪ miDiagnostics, speaker to be announced -
12:45
Time for networking and to visit the exhibition and innovation square.
Q&A: Funding opportunities of Top Sector Life Sciences & Health @ Health~Holland Booth
Are you in search of suitable ways to fund your innovative R&D solutions in the Life Sciences & Health (LSH) sector and are you part of a public-private partnership? Then come to the Q&A session of the Top Sector LSH and get informed. Three of our experts are happy to give you insight in the Top Sector’s funding opportunities and the terms and conditions. -
14:00
Parallel afternoon programme
Human Microbiome: Novel therapeutic strategies and market developments
Hosted by PwC
Presentations by:
▪ Dries Budding, CEO inBiome
▪ to be announcedCell- and gene based therapeutics
Hosted by Progress-PME
Presentations by
▪ Karin Hoogendoorn, Sr. Director CMC portfolio management/CMC lead uniQure
▪ Marc Kamp, Executive Director Quality, Neogene Therapeutics
▪ to be announced -
15:15
Time for networking and to visit the exhibition and innovation square.
-
16:00
-
Announcement winner Investors Forum
The winner of the Investors Forum will be awarded a partnering ticket, national or international with a total value of EUR 2,500 and will present their pitch.
-
Closing keynote lecture ´The positive side-effects of the COVID-19 pandemic´
by Hans Schikan, PharmD, Special Envoy Vaccines Dutch Ministry of Health, Welfare and Sport
The ongoing COVID-19 pandemic is devastating, for individual people, societies at large and economies alike. At the same time, due to this ‘external enemy’ the world has seen unprecedented collaboration, speedy review of innovations and risk sharing between the public and private sector. Which of these ‘positive side-effects’ of the pandemic should we try to foster and keep, also in the post-pandemic era? What are the lessons learnt?
-
17:15
Drinks, bites, networking and visit the exhibition and innovation square!